Multivariate survival analysis of children with medulloblastoma--a single-center experience.
The authors sought to evaluate the treatment outcome of children with medulloblastoma at a single institution. Forty-two children were analyzed. Eighty-six percent of the children who received chemotherapy were treated with cisplatin-based chemotherapy. No factors were found to affect outcome significantly. Compared with children treated before 1994 at the same institution, the median survival time was significantly longer (40 vs. 25 months, p = .0003). The authors conclude that some improvement of treatment outcome for children with medulloblastoma seemed to be achieved.
Division of Hematology and Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Shih-Hsiang
SH
Chen
Li-Yu
LY
Liu
Tang-Her
TH
Jaing
Chen-Kan
CK
Tseng
Kuang-Lin
KL
Lin
Tai-Ngar
TN
Lui
D000293:Adolescent; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D002528:Cerebellar Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy; D015999:Multivariate Analysis; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016019:Survival Analysis
D000972:Antineoplastic Agents, Phytogenic; D011838:Radiation-Sensitizing Agents; D005047:Etoposide; D002945:Cisplatin